Rheumatologists prescribe rituximab for induction and maintenance treatment for anti-neutrophil cytoplasm antibody (ANCA) associated vasculitides (AAV). Maintenance treatment typically employs fixed-schedule dosing, but in the recent maintenance of remission using rituximab in systemic ANCA-associated vasculitis II (MAINRITSAN2) trial, researchers from the French Vasculitis Study Group examined whether individually tailored maintenance dosing might work better.
“The main objectives of the MAINRITSAN2 trial were to determine whether an individually tailored infusion strategy would maintain remission with fewer relapses, fewer infusions and fewer infections,” says Loïc Guillevin, professor in the Department of Internal Medicine at Hôpital Cochin at Université Paris Descartes, France. “The other objective was to determine whether a reinfusion strategy based on ANCA and circulating CD19+ B cells would accurately predict relapses.”
The Study Details
The study included patients diagnosed with initial-onset or relapsing granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) from November 2012–November 2013 who were in complete remission following induction. Of those 162 patients, 117 (72.2%) were diagnosed with GPA, and 45 (27.8%) were diagnosed with MPA.